Company profile for Taris Biomedical

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

TARIS® is advancing TAR-200 for the treatment of muscle invasive bladder cancer (MIBC). This program continuously administers the approved agent gemcitabine for multiple weeks. We believe that TAR-200 has the potential to harness both direct antitumor and immuno-oncologic activity without meaningful systemic drug exposure, yielding a powerful therapy and mitigating systemic side-effects.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
113 Hartwell Avenue Lexington, MA 02421
Telephone
Telephone
781-676-7750
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Johnson & Johnson acquires TARIS Biomedical
Johnson & Johnson acquires TARIS Biomedical

24 Dec 2019

// THE PHARMALETTER

https://www.thepharmaletter.com/in-brief/brief-johnson-johnson-acquires-taris-biomedical

THE PHARMALETTER
24 Dec 2019

https://www.biospace.com/article/releases/taris-announces-positive-results-of-phase-1b-trial-of-tar-200-in-muscle-invasive-bladder-cancer/

BIOSPACE
26 Jun 2019

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty